Patents by Inventor Tony Dung-Ling Yao

Tony Dung-Ling Yao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IgE binding proteins and uses thereof
    Patent number: 12234297
    Abstract: Provided herein are IgE-binding VHH domains, polypeptides, and proteins, and methods of using such IgE-binding polypeptides and proteins to modulate the biological activity of IgE.
    Type: Grant
    Filed: August 2, 2024
    Date of Patent: February 25, 2025
    Assignees: Phylaxis Bioscience, LLC, Inhibrx Biosciences, Inc.
    Inventors: Bryan R. Becklund, Kyle S. Jones, Andrew M. Eckles, Brendan P. Eckelman, Tony Dung-Ling Yao
  • SIGLEC-8 BINDING PROTEINS AND USES THEREOF
    Publication number: 20250042997
    Abstract: Provided herein are Siglec-8 binding proteins, and methods of using Siglec-8 binding proteins to modulate the biological activity of Siglec-8.
    Type: Application
    Filed: October 22, 2024
    Publication date: February 6, 2025
    Inventors: Tony Dung-Ling Yao, Andrew M. Eckles, Jacob J. Gano, Bryan Becklund, Brendan P. Eckelman
  • IgE BINDING PROTEINS AND USES THEREOF
    Publication number: 20250019464
    Abstract: Provided herein are IgE-binding VHH domains, polypeptides, and proteins, and methods of using such IgE-binding polypeptides and proteins to modulate the biological activity of IgE.
    Type: Application
    Filed: August 2, 2024
    Publication date: January 16, 2025
    Inventors: Bryan R. Becklund, Kyle S. Jones, Andrew M. Eckles, Brendan P. Eckelman, Tony Dung-Ling Yao
  • SIGLEC-8 BINDING PROTEINS AND USES THEREOF
    Publication number: 20230406925
    Abstract: Provided herein are Siglec-8 binding proteins, and methods of using Siglec-8 binding proteins to modulate the biological activity of Siglec-8.
    Type: Application
    Filed: July 28, 2023
    Publication date: December 21, 2023
    Inventors: Tony Dung-Ling Yao, Andrew M. Eckles, Jacob J. Gano, Bryan Becklund, Brendan P. Eckelman
  • METHODS FOR IMMUNOTHERAPY
    Publication number: 20230192807
    Abstract: The present invention encompasses methods for reducing the number of target cells in a subject, such as cancer cells. The methods include administration of genetically-modified human immune cells expressing a chimeric antigen receptor or exogenous T cell receptor, which have specificity for an antigen on the target cells. Administration of the genetically-modified immune cells is preceded by the administration of a tolerance regimen, followed by administration of a lymphodepletion regimen, to improve efficacy of the therapy and persistence of the cells in vivo.
    Type: Application
    Filed: May 14, 2021
    Publication date: June 22, 2023
    Applicant: Precision BioSciences, Inc.
    Inventors: Christopher Ryan Heery, Alan F. List, Leo Luznik, Tony Dung-Ling Yao